Specificity Improved for Urinary Antigen Testing
By LabMedica International staff writers Posted on 23 May 2017 |
Image: The Cryptococcal Antigen Lateral Flow Assay (CrAg LFA) Immy test (Photo courtesy of Immuno-Mycologics).
The cryptococcal antigen lateral flow assay (CrAg LFA) Immy test is standardized for a fast screening point-of-care test for cryptococcosis, detecting cryptococcal antigen in serum and cerebrospinal fluid (CSF).
A delay in laboratory diagnosis is related to sequelae and death and therefore early diagnosis is the key to decrease the high lethality rate due to cryptococcosis. Urine screening would be ideal as a noninvasive approach, but previous studies have shown that fresh urine present false positive results.
Scientists at the National Institute of Infectious Diseases Evandro Chagas performed a prospective cohort study from April 2014 to April 2015 on 77 volunteers: 53 HIV-positive (CD4+ T cell less than 200 cells/mm3) patients, 18 healthy individuals (negative controls), and six HIV-positive patients with active proven cryptococcosis (positive controls). Healthy individuals were included as a negative control and patients presenting proven cryptococcosis as a positive control.
Cryptococcal antigen testing was performed in blood serum and urine from each volunteer using the CrAg LFA Immy test. Each fresh urine sample was tested under two conditions: unheated (untreated) and heated (treated) by five minutes incubation at 100 °C. Clinical specimens such as blood, CSF, and urine were subsequently cultivated to investigate cryptococcal infection. The CrAg LFA in serum samples was considered as the gold standard.
The investigators reported that 24/53 HIV-positive volunteers had a CrAg LFA–positive profile (42.3%) when untreated fresh urine was tested. When heated, only eight samples were positive (15%), presenting 100% of agreement with the positive results obtained from serum samples submitted to CrAg LFA Immy assay. Out of those eight positive patients, five had proven cryptococcosis (positive culture for Cryptococcus neoformans in CSF and/or blood culture) and three patients had cryptococcal antigenemia (negative for Cryptococcus in blood and CSF cultures). The untreated fresh urine has shown 16 false positive results (30.2%). After treatment, those urine samples were negative, as confirmed by negative results in the serum.
The authors concluded that heating of urine prior testing dramatically improved the test’s specificity without compromising the test’s sensitivity. This crucial step has dramatically increased the specificity without compromising test sensitivity, with two additional advantages: no need of enzymatic treatment or sample dilution. The study was published on the journal Public Library of Science Neglected Tropical Diseases.
A delay in laboratory diagnosis is related to sequelae and death and therefore early diagnosis is the key to decrease the high lethality rate due to cryptococcosis. Urine screening would be ideal as a noninvasive approach, but previous studies have shown that fresh urine present false positive results.
Scientists at the National Institute of Infectious Diseases Evandro Chagas performed a prospective cohort study from April 2014 to April 2015 on 77 volunteers: 53 HIV-positive (CD4+ T cell less than 200 cells/mm3) patients, 18 healthy individuals (negative controls), and six HIV-positive patients with active proven cryptococcosis (positive controls). Healthy individuals were included as a negative control and patients presenting proven cryptococcosis as a positive control.
Cryptococcal antigen testing was performed in blood serum and urine from each volunteer using the CrAg LFA Immy test. Each fresh urine sample was tested under two conditions: unheated (untreated) and heated (treated) by five minutes incubation at 100 °C. Clinical specimens such as blood, CSF, and urine were subsequently cultivated to investigate cryptococcal infection. The CrAg LFA in serum samples was considered as the gold standard.
The investigators reported that 24/53 HIV-positive volunteers had a CrAg LFA–positive profile (42.3%) when untreated fresh urine was tested. When heated, only eight samples were positive (15%), presenting 100% of agreement with the positive results obtained from serum samples submitted to CrAg LFA Immy assay. Out of those eight positive patients, five had proven cryptococcosis (positive culture for Cryptococcus neoformans in CSF and/or blood culture) and three patients had cryptococcal antigenemia (negative for Cryptococcus in blood and CSF cultures). The untreated fresh urine has shown 16 false positive results (30.2%). After treatment, those urine samples were negative, as confirmed by negative results in the serum.
The authors concluded that heating of urine prior testing dramatically improved the test’s specificity without compromising the test’s sensitivity. This crucial step has dramatically increased the specificity without compromising test sensitivity, with two additional advantages: no need of enzymatic treatment or sample dilution. The study was published on the journal Public Library of Science Neglected Tropical Diseases.
Latest Microbiology News
- Integrated Solution Ushers New Era of Automated Tuberculosis Testing
- Automated Sepsis Test System Enables Rapid Diagnosis for Patients with Severe Bloodstream Infections
- Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases
- Clinical Decision Support Software a Game-Changer in Antimicrobial Resistance Battle
- New CE-Marked Hepatitis Assays to Help Diagnose Infections Earlier
- 1 Hour, Direct-From-Blood Multiplex PCR Test Identifies 95% of Sepsis-Causing Pathogens
- Mouth Bacteria Test Could Predict Colon Cancer Progression
- Unique Metabolic Signature Could Enable Sepsis Diagnosis within One Hour of Blood Collection
- Groundbreaking Diagnostic Platform Provides AST Results With Unprecedented Speed
- Simple Blood Test Combined With Personalized Risk Model Improves Sepsis Diagnosis
- Blood Analysis Predicts Sepsis and Organ Failure in Children
- TB Blood Test Could Detect Millions of Silent Spreaders
- New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours
- New Tuberculosis Test to Expand Testing Access in Low- and Middle-Income Countries
- Rapid Test Diagnoses Tropical Disease within Hours for Faster Antibiotics Treatment
- Rapid Molecular Testing Enables Faster, More Targeted Antibiotic Treatment for Pneumonia